Updated May 2026 · 7 peptides indexed
The evidence behind every peptide.
A vendor-neutral, citation-dense reference for peptide therapies. Every claim sourced. Evidence graded on a four-tier scale. Reviewed against current FDA compounding status.
What this is
- Every claim linked to a numbered source — PubMed, FDA documents, or named experts with dates.
- Animal data, case reports, and human RCTs separated — never blended.
- Regulatory status with a specific effective date on every page.
What this is not
- No dosing protocols. Dosing decisions belong with a licensed prescriber.
- No vendor recommendations on reference pages.
- Not medical advice. Not a substitute for clinical judgment.
The four-tier evidence framework
Methodology →Applied consistently across every page so you can compare peptides on the same scale, not on marketing claims.
Tier 1
FDA-Approved
Completed Phase 3 trials, FDA approval for at least one indication.
Tier 2
Clinically Studied
Multiple human RCTs (n>50 total), available through licensed compounding.
Tier 3
Limited Human Evidence
Some published human data (case reports, small studies), strong animal data.
Tier 4
Animal Data Only
No published human trials. Mechanism inferred from animal models.
Recently updated
View all 7 entries →Active regulatory event
See the timeline14 peptides returned to Category 1 status on April 23, 2026.
Final review at the Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026.